Celebrate American Heart Month in FebruaryJanuary 31st, 2019
Global ELISA Market to Grow at a CAGR of 5.5% through 2028January 30th, 2019
MEDICA 2019 - World Forum for Medicine
Düsseldorf, GermanyBooth No.: 3/D35-2
AACC Annual Scientific Meeting and Clinical Lab Expo
Anaheim Convention Center ~ Anaheim, CABooth No.: 2627
Thanks to Block Scientific, I was able to procure the re-certified Bayer DCA 2000+ without hassles and get the lab back in operation. The
device works perfectly and I look forward to doing more business with Block Scientific.
--- Mathew Anderson, New Jersey
Enzyme immunoassay for the in-vitro semi-quantitative or quantitative determination of IgG antibodies against Borrelia burgdorferi in human serum, plasma and CSF. Infections with all three B. burgdorferi subspecies (garinii, afzelii and sensu strictu) are detected.
Borrelia burgdorferi, a bacterium of the Spirochaetaceae, is the ethiologic agent of Lyme disease (Borreliosis) being the most common disease in Europe and the USA transmitted by tics (Ixodes sp.). Lyme borreliosis is a multi-systemic disease with a broad spectrum of clinical symptoms. A typical symptom of the acute phase is the erythema chronicum migrans (ECM), often accompanied by flue-like symptoms. In later stages of the disease arthritis, carditis, as well as neurological and dermatological manifestations may occur.
Lyme borreliosis can be treated with antibiotics in all stages. Therefore, a safe and sensitive laboratory diagnosis of Lyme borreliosis, also detecting the early stage of diseases, is of major importance, since an early treatment is most appreciated. IgM antibodies usually appear approximately three weeks after the infection, IgG antibodies after four to six weeks. The
early immune reaction is mainly directed against the 14 kD region of the flagellin and the OspC (Outer surface protein C).
Usually the acute phase is indicated by high titers of IgM antibodies. Elevated IgG titers with low or without IgM antibodies may occur when the borreliosis is subsiding (due to therapy or spontaneously) or during the chronic stage. The performance of the Borrelia IgG ELISA is important especially to detect a borreliosis even in cases showing negative 14 kD + OspC titers and to monitor the immune status.
The Borrelia IgG ELISA employs the very highly specific recombinant Borrelia burgdorferi VlsE antigen and a highly specific crude lysate antigen blend from Borrelia burgdorferi sensu strictu, B. afzelii and B. garinii and therefore determines IgG antibodies with extremely high sensitivity and specificity.